派格生物医药-B(02565)就申请建议实行H股全流通向中国证监会备案

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, representing approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of 102 million unlisted shares [1] - The conversion will result in the issuance of H-shares, which are traded on the Hong Kong Stock Exchange [1] - The newly converted shares will account for about 26.35% of the company's total issued shares as of the announcement date [1]